QTORIN rapamycin 3.9 percent gel

The economic evidence in this report consists of a sponsor-projected annual pricing range and historical estimates of hospital charges for pediatric lymphatic malformations. The sponsor presented an annual pricing range of approximately $100,000 to $200,000 per patient, without identifying that range as an established ASP or WAC. The inpatient study reported average charges of $30,995 per admission using data from 2000, 2003, 2006, and 2009. These historical charges concern lymphatic malformations broadly and are not current treatment costs specific to microcystic lymphatic malformations.

The report contains no QTORIN-specific budget impact model. The available pricing projection and historical hospital-charge estimates do not establish treatment-related cost offsets, incremental payer expenditure, or cost effectiveness.